Dialister spp. Modulation for Spondyloarthritis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spondyloarthritis (SpA) primarily focus on anti-inflammatory therapies that do not address the underlying causes of the disease, and there is a lack of effective preventive measures, with gut inflammation playing a significant role in disease activity but the relationship between gut microbial composition and disease activity markers remaining unclear.
Innovation Solution
Modulating the abundance of Dialister spp. in the gut, specifically using compositions comprising certain Dialister OTUs, to reduce inflammation in SpA patients, either through fecal transplants or oral formulations, and identifying compounds that inhibit the growth of disease-associated Dialister spp. to decrease intestinal abundance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anti-inflammatory therapies are used to treat SpA, then inflammation symptoms are reduced, but the underlying causes of the disease are not addressed
Solution Approach 1:
The patent extracts and targets the specific harmful bacteria (Dialister spp.) from the gut microbiota that are identified as underlying causes of SpA. By using compositions that specifically inhibit or eliminate these pathogenic bacteria, the treatment addresses the root cause rather than just suppressing inflammation symptoms, thereby improving both symptom relief and long-term disease prevention
Solution Approach 2:
The patent introduces compositions (such as probiotics, prebiotics, or antimicrobial agents) as intermediaries to modulate the gut microbiota. These compositions act as mediators between the host immune system and the gut bacteria, restoring microbial balance and reducing the population of Dialister spp., which in turn reduces inflammation and addresses the underlying disease mechanism
2Productivity
If current SpA treatments are used, then disease activity is partially controlled, but preventive measures are lacking
Solution Approach 1:
The patent employs preliminary action by modulating gut microbiota composition before disease flare-ups occur. By maintaining a healthy balance of gut bacteria through targeted compositions, the treatment prevents the overgrowth of pathogenic Dialister spp., thereby preventing disease activation in the first place and providing long-term protection rather than just responding to active disease
Solution Approach 2:
The patent enables the patient's own gut microbiota to serve as a therapeutic agent. By restoring beneficial bacteria and eliminating harmful ones, the patient's microbiome becomes self-regulating, continuously preventing disease recurrence without requiring ongoing high-dose anti-inflammatory medications, thus providing sustained long-term prevention
3Adaptability or versatility
If the relationship between gut microbial composition and disease activity is not understood, then targeted treatments cannot be developed, but treating all SpA patients with the same approach is ineffective
Solution Approach 1:
The patent applies local quality by tailoring the treatment composition to the specific gut microbiota profile of each patient. Rather than using a uniform treatment for all SpA patients, the composition is customized based on individual microbial analysis, targeting the specific pathogenic strains present in each patient's gut while preserving beneficial bacteria, thereby achieving personalized effective treatment
Solution Approach 2:
The patent introduces dynamics by making the treatment adaptable and adjustable over time. The composition can be modified based on changes in the patient's gut microbiota composition and disease activity, allowing the treatment to evolve with the patient's condition. This dynamic approach enables continuous optimization of therapy based on real-time microbial monitoring
Data Source
Figure 1a~1c
Figure 2
Figure 3
AI summary
The present invention relates to the field of inflammation-associated disorders or conditions, more particularly to gut inflammation and/or joint inflammation, even more particularly to spondyloarthritis. Provided herein are means and methods to treat, prevent and/or reduce the severity of inflammation-associated disorders or conditions in a subject in need thereof.